[Therapy adherence to immunomodulator treatment in patients with multiple sclerosis].

Introduction: Immunomodulator treatment modifies the course of the disease in patients with multiple sclerosis. The patient's adequate adherence with the treatment regimen is absolutely essential.

Aims: To determine the real adherence with first-line immunomodulator treatment and to try to find out what factors may influence adequate adherence with the treatment.

[Meningeal and Guillain-Barrè syndrome in a patient with rheumatoid arthritis receiving adalimumab therapy].

Adalimumab is a recombinant human monoclonal antibody that blocks the effects of tumor necrosis factor-alpha, and is presently used for treatment of rheumatoid arthritis, with demyelination being a potential adverse effect. A 31 year-old male with seropositive rheumatoid arthritis presented with diarrhea after the second injection of adalimumab. He was treated with ciprofloxacin.